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INTRODUCTION
Biotechnology is a growing and important industry in most developed
countries. The possibilities for commercial gain from biotechnology are thought
to be enormous. Post modern economies are based on new ideas rather than
natural resources such as, land, labor, capital, or strategic location (for example,
the old silk trail). New ideas require investment to develop of new products and
processes, that will create wealth of nations in the twenty-first century.
To create this wealth, institutional arrangements that lower the cost of
investing in biotechnology research and development will be needed. For
example, firms want to be certain their inventions will be protected from
predators at a low cost. Without such protection, investors may move their
investments elsewhere. Another important cost is related to the licensing of
new products. In the business of new ideas, time is important because
competitors will be close behind. Thus firms want a regulatory process that is
quick and careful. Finally, access to world markets is important because no
domestic market is large enough to absorb the cost of developing these new
products. Therefore, access to foreign markets is an important issue in
determining where firms will invest their money.
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This new investment opportunity is largely contained in the private sector.
Governments are supplying only regulations, along with some training and
basic research, while the private sector supplies the capital and management.
While this division of responsibility concerns some, the future biotechnology
industry will be driven by private capital attempting to earn a return for private
investors.
This paper will address the two issues of regulation and economics. First, the
impact of regulations of biotechnology from a domestic and trade perspective
will be examined. Second, the domestic market conditions for new products
will be looked at, followed by discussion of some of the potentials and impacts
these new products will have on Canadian agriculture. Obviously, the surface
can only be scratched because these are complex issues.
THEORETICAL ISSUES
The economics of regulation is a well-developed field of study. The early work
in this field was done by George Stigler, who linked the economic performance
of an economy to the existing regulatory environment. In this paper, a short
description of a model of regulation is provided by Ulrich, Furtan, and Schmitz
(1987).
If agricultural products are created through the use of two technologies (with
or without biotechnology), it can be assumed that the consumer will view them
as two different products. The production possibilities curve (Figure 1) depicts
the trade-off that occurs in the level of production of the two different products.
If the regulations block the amount of biotechnology the economy produces
and the relative prices for the two products is R0, the production of only one
product occurs at X1. If the regulators allow both products to be sold, then
production occurs at Z1 along R1. Clearly, the level of welfare in the economy
has gone up because consumers can now purchase the type of product they
prefer.
Over time, technology change will shift the frontier from X1Y1 to X1Y2 and
the optimal production point will move from Z1 to Z2,holding the relative prices
constant. By blocking the introduction of biotechnology products, the
agricultural sector loses more over time. If the relative prices change from R2 to
R3, then the production of biotechnology products drops but the sector is still
better off at point X1.
REGULATION IN THE BIOTECHNOLOGY INDUSTRY
Regulation of agricultural biotechnology and related products is under the
review of the federal government.1  At least three departments are involved:
Agriculture and Agri-Food Canada, Health Canada, and Environment Canada.
1Source: Ulrich, A., W.H. Furtan, A. Schmitz, 1987. The cost of a licencing system regulation: an
example from Canadian prairie agriculture. Journal of Political Economy 95
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The principal department in charge of agricultural biotechnology is Agriculture
and Agri-Food Canada, which regulates issues such as transgenic plants under
the Seeds Act, microbial products such as animal feeds under the Feeds Act,
microbial growth supplements under the Fertilizers Act, microbial pest control
products under the Pest Controls Product Act, and veterinary vaccines and
biologics under the Health of Animals Act. The Biotechnology Strategies and
Coordination Office is under the direction of Agriculture and Agri-Food
Canada and is responsible for importation and phytosanitary measures under
the Plant Protection Act and the Health of Animals Act. It is also responsible for
food safety and standards and prevention of fraud under the Canadian
Agricultural Products Act. While this system is similar to that in the United
States, and is consistent with the European Economic Community’s premarket
clearance, it still leaves the Canadian industry with a fragmented system.
Environment Canada is involved, as well, in the regulatory process. It is the
responsibility of this department to set environmental assessment standards for
food products. This is done in consultation with Agriculture and Agri-Food
Canada but Environment Canada is responsible under the Canadian
Environmental Protection Act for making certain that new food products
resulting from biotechnology are safe.
Health Canada is concerned with food safety issues and particularly new food
products using biotechnology. The formal regulatory process administered by
Health Canada comes under the Food and Drug Act, but the policy that is in
place has not yet been approved by the government of Canada. Anyone wishing
to introduce a novel food must notify the Health Department 90 days in
advance of marketing the product. The department is then given 98 days to
request more information.
The Novel Food Regulations are clearly aimed at addressing consumer’s
concerns over food safety. They specify that before a novel food can be
marketed in Canada the firm must notify Health Canada of the intention to do
so 90 days in advance. A novel food is defined as
• a substance that has previously not been used in Canada or will result
from a process that has not previously been used for food in Canada;
• an existing food that has been modified by genetic manipulation and
exhibits one or more characteristics that were previously not
identified in that food or food that results from production by
genetically manipulated organisms exhibiting such new
characteristics;
• food containing microorganisms that have previously not been used as
food or to process food; and
• food that is substantially modified from the traditional product or is
manufactured by a process that has been substantially modified from
the traditional process.
An example is bovine somatotropin (BST), which is given to dairy cattle.
Under this regulation, BST is a novel food and must therefore be examined by
both Agriculture and Agri-Food Canada and Health Canada. Clearly, there is an
overlap of jurisdiction, as well as a difference of opinion as to what is
acceptable and safe.
From an economic perspective, this regulation is expensive for firms that
introduce new products. Using an economic framework, this slowdown of
technology and the extra cost make investment in Canada more expensive and
more risky.
INTELLECTUAL PROPERTY RIGHTS
The area of intellectual property rights has grown in importance as countries
recognize that the postmodern economy is built on ideas rather than on
resources or population. For companies to invest and create wealth, they must
be able to capture some of the wealth. If they are not able to capture wealth,
they will have no incentive to invest. There are many reasons why companies
may not be able to capture wealth, such as the nature of the good produced
(public vs. private), market and institutional failures, and information
problems. Institutional problems, such as having others steal your invention,
can be corrected through legislative changes that provide affordable protection
for innovators. This is why the issue of property rights is an important
legislative concern and is a form of market failure. Countries disagree on how
best to handle this issue. Some feel that by protecting innovations, rich
countries will be able to advance their economies while poor countries will not
be able to afford the investments. These people call for larger public
investments in agricultural research. Others argue that private research is the
most efficient way to allocate resources to much of the agriculture sector and
this can be achieved only by protecting property rights, including intellectual
property. Given the reduction in government budgets and the shrinking
political power of agriculture, the latter group is the most likely to win the day
for now.
In the case of agricultural biotechnology, there are two ways that new
material can be protected and private investment facilitated: through patents
and plant breeders’ rights. Canadian law treats these two issues differently and,
in the case of patents, differently than the United States.
To get an invention patented in Canada, four criteria must be met. The first is
to demonstrate that the invention is new and has not been done before. Second,
the invention must be proven to have some commercial value and not be trivial.
Third, the invention must fall or fit into a predetermined category. Finally, it
must demonstrate some progress or advancement. Once these criteria are met,
an application can be made under the Patent Act to the commissioner of
patents for Canada.
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In a recent paper Churchill (1996), pointed out that Canada has not fully
come to grips with its policy on the patenting of living material. Currently, this
is an important difference between Canada and the United States, and it will be
seen as a cost to investors in Canada when compared to the United States. This
represents a large transaction cost in Canada and will lower the level of
investment made in Canada in the area of agriculture biotechnology.
A second method to protect some biotechnology products and processes is
the Plant Breeder’s Rights Act. This act protects plants through the process of
granting breeder’s rights to certain varieties by restricting others from using the
varieties without the payment of royalties. The term plant variety is defined to
mean “any cultivar, breeding line, or hybrid of a prescribed category of plant
that can be cultivated” (Churchill). The new variety must be stable,
distinguishable from other varieties, and homogenous. While useful, this act
provides only limited protection to intellectual property.
The final point that needs to be made is that there is a gradual consolidation
of regulation on intellectual property protection in developed countries. Clearly,
firms will go where they have the greatest chance of profit, and if a country
taxes firms by failing to protect investments, they will move to more acceptable
climes. This problem is forcing some countries such as Canada (that wish to
attract this type of investment) to align their regulatory systems with those of
the United States and the European Community. Canadian farmers also stand to
lose competitiveness if new technology is not made available to them at the
same time it is made available to their competitors.
INTERNATIONAL TRADE AND MARKET ACCESS
There are two issues of concern around market access and international trade.
The first is consumer acceptance. There is no incentive to produce a product
that consumers will not buy because of perceived (or other) concerns over
safety. Second, there are rules that affect the trade of agricultural biotechnology
products. Both of these concerns must be dealt with by firms that plan to
introduce new products into the marketplace.
If farmers produce a product that some consumers will not purchase, it must
be segregated from other similar products. The case in point is transgenic
canola, which is acceptable in the Canadian, American, and Japanese markets
but not the European market. This segregation must be done in such a way as
to meet the standards of the market; that is, consumers want to be certain of the
origin of the products they are consuming. Segregation of products is
expensive, and its cost may block the introduction of new food products. Mayer
(1996) examined this question and showed that the cost advantages of
transgenic canola are such that farmers will grow the new varieties even with
the cost of segregation. She estimated that Canadian prairie farmers would
benefit in the order of $441 million annually if transgenic canola is accepted in
all markets and $215 million annually if only Japan blocked the new product.
She also showed that the lack of market access can completely block the
introduction of transgenic canola.
Since producers are growing transgenic canola, they must assume that
consumers will purchase the product once it is on the shelf. A recent survey of
consumers in the United States and Europe reported that 73 percent of those in
America would purchase food derived from transgenic crops while only 15
percent in Europe would do so, if they had the choice (Wadman, 1996). This
suggests that agricultural biotechnology is going to have a more difficult time
gaining market access in Europe than in America. The situation in the
Canadian market is not altogether clear; we have accepted transgenic canola
but not BST.
The rules for trade in agricultural biotechnology products are set by the
World Trade Organization (WTO). There is a recognition internationally that
technology is outpacing the existing legal regimes in most countries. Also, most
agree that investment dollars will flow to those countries that provide
protection for intellectual property. Given these concerns, the WTO has set
minimum standards for the protection of agricultural biotechnology products
and trade in such products.
The WTO rules include: (1) love thy neighbors equally and not less than
thyself, that is, rules for domestic firms must also be made available to others;
(2) patent rules must be transparent, that is, individual firms must be able to
find out exactly what the rules are and how they are applied; (3) the patent
rules must be enforced by the home country; (4) any product or process is
patentable for 20 years from time of filing; (5) there must be compulsory
licensing of patents so that technology is available to other firms; and (6) the
patenting of life forms is excluded.
The WTO has also set rules regarding trade in genetically altered feeds and
foods. The sanitary and phyotosanitary standards require that the importation
of new foods be based on the following four criteria: scientific basis, risk
assessment, acceptable risk, and national treatment. While these rules sound
good, there still is no agreement on how they will be applied. For example,
whose scientific evidence or opinion will be accepted, and what is acceptable
risk? The debate over the safety of certain growth hormones in cattle feed is an
issue that some say is real and others say is just a poorly disguised trade barrier.
This still leaves market access very much open to question.
CONCLUSIONS
Agricultural biotechnology holds many promises for the future as a major
investment opportunity. For Canada to compete with other major players, the
costs of doing business in Canada in terms of regulation must be lowered and
the appropriate institutional arrangements in place to protect intellectual prop-
erty must be put in place. Market access remains a concern, but it can best be
tackled through education and work with other trading nations through the WTO.
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Canadian farmers need to be concerned with developments in the field of
biotechnology. As they will be using and producing the products, their
economic livelihood depends on the orderly regulation of this sector. To be
certain this occurs, they are going to have to be actively involved in the process.
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